4128 Stock Overview
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Microbio Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$44.80 |
52 Week High | NT$63.87 |
52 Week Low | NT$42.80 |
Beta | 1.38 |
1 Month Change | -4.88% |
3 Month Change | -10.93% |
1 Year Change | -26.72% |
3 Year Change | -13.85% |
5 Year Change | 292.69% |
Change since IPO | 346.16% |
Recent News & Updates
Shareholder Returns
4128 | TW Personal Products | TW Market | |
---|---|---|---|
7D | 3.2% | 1.0% | 1.1% |
1Y | -26.7% | -8.6% | 26.7% |
Return vs Industry: 4128 underperformed the TW Personal Products industry which returned -8.6% over the past year.
Return vs Market: 4128 underperformed the TW Market which returned 26.7% over the past year.
Price Volatility
4128 volatility | |
---|---|
4128 Average Weekly Movement | 4.5% |
Personal Products Industry Average Movement | 3.4% |
Market Average Movement | 4.2% |
10% most volatile stocks in TW Market | 7.9% |
10% least volatile stocks in TW Market | 1.9% |
Stable Share Price: 4128 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4128's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | n/a | Hsien-Shou Kuo | https://www.microbio.com.tw |
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for ameliorating fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia and menstrual discomfort. Its pre-clinical stage products include SNA-03 and SNA-07 for cancer immune therapy; SNP-630 to treat non-alcoholic steatohepatitis; FB918 for the treatment of non-allergic eosinophilic asthma; and SNS812 for Cov-flu.
Microbio Co., Ltd. Fundamentals Summary
4128 fundamental statistics | |
---|---|
Market cap | NT$25.10b |
Earnings (TTM) | -NT$1.18b |
Revenue (TTM) | NT$1.59b |
15.8x
P/S Ratio-21.3x
P/E RatioIs 4128 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4128 income statement (TTM) | |
---|---|
Revenue | NT$1.59b |
Cost of Revenue | NT$987.51m |
Gross Profit | NT$603.88m |
Other Expenses | NT$1.78b |
Earnings | -NT$1.18b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.11 |
Gross Margin | 37.95% |
Net Profit Margin | -74.14% |
Debt/Equity Ratio | 0% |
How did 4128 perform over the long term?
See historical performance and comparison